for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

6185.HK

Latest Trade

238.00HKD

Change

-11.20(-4.49%)

Volume

2,163,660

Today's Range

236.00

 - 

255.80

52 Week Range

30.55

 - 

285.80

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
249.20
Open
253.80
Volume
2,163,660
3M AVG Volume
42.35
Today's High
255.80
Today's Low
236.00
52 Week High
285.80
52 Week Low
30.55
Shares Out (MIL)
222.65
Market Cap (MIL)
55,484.36
Forward P/E
-997.60
Dividend (Yield %)
--

Next Event

Cansino Biologics Inc Annual Shareholders Meeting

Latest Developments

More

Cansino Biologics Says Recombinant Novel Coronavirus Vaccine Got Military Specially-Needed Drug Approval

Cansino Biologics Got Clinical Trial Application Approval For Recombinant Novel Coronavirus Vaccine

Canadian clinical trials to test CanSino Biologics Covid-19 vaccine candidate

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cansino Biologics Inc

CANSINO BIOLOGICS INC., formerly Tianjin CanSino Biotechnology Inc., is a China-based company principally engaged in the research and development, manufacture and commercialization of vaccine products for human use. The Company’s core products consist of two vaccine candidates, namely MCV4 candidate and MCV2 candidate. The Company mainly operates its business in the domestic market.

Industry

Biotechnology & Drugs

Contact Info

+86.22.58213600

http://www.cansinotech.com.cn/

Executive Leadership

Xuefeng Yu

Executive Chairman of the Board, Chief Executive Officer, General Manager

Shou Bai Chao

Chief Operating Officer, Deputy General Manager, Executive Director

Dongxu Qiu

Senior Vice President, Deputy General Manager, Executive Director

Huihua Mao

Senior Vice President, Deputy General Manager

Zhu Tao

Chief Scientific Officer, Deputy General Manager, Executive Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2019

0.0K

2020(E)

0.3K
EPS (CNY)

2019

-0.770

2020(E)

-0.230
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
34.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.34
LT Debt To Equity (MRQ)
9.37
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

China's CanSino in talks for COVID-19 vaccine Phase III trial overseas

Chinese vaccine developer CanSino Biologics is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, its co-founder said on Saturday.

CanSino's COVID-19 vaccine candidate approved for military use in China

China's military has received the greenlight to use a COVID-19 vaccine candidate developed by its research unit and CanSino Biologics <6185.HK> after clinical trials proved it was safe and showed some efficacy, the company said on Monday.

BRIEF-Cansino Biologics Says Recombinant Novel Coronavirus Vaccine Got Military Specially-Needed Drug Approval

* RECOMBINANT NOVEL CORONAVIRUS VACCINE GOT MILITARY SPECIALLY-NEEDED DRUG APPROVAL WITH A VALID PERIOD FOR 1 YEAR

BRIEF-Cansino Biologics, Precision Nanosystems To Co-Develop COVID-19 RNA Vaccine

* CANSINO BIOLOGICS AND PRECISION NANOSYSTEMS ANNOUNCE COLLABORATION TO CO-DEVELOP A COVID-19 RNA VACCINE

BRIEF-Cansino Biologics Got Clinical Trial Application Approval For Recombinant Novel Coronavirus Vaccine

* GOT CLINICAL TRIAL APPLICATION APPROVAL FOR RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) FROM HEALTH CANADA Source text for Eikon: Further company coverage:

Chinese coronavirus vaccine could be tested, manufactured in Canada

China's CanSino Biologics Inc <6185.HK>, the company behind one of the few coronavirus vaccine candidates already in clinical trials, is collaborating with Canada's National Research Council to "pave the way" for future trials in Canada, the research council said on Tuesday.

BRIEF-Cansino Biologics Collaborates With National Research Council Of Canada To Advance Clinical Trial For Recombinant Covid-19 Vaccine

* COLLABORATION WITH NATIONAL RESEARCH COUNCIL OF CANADA TO ADVANCE CLINICAL TRIAL FOR RECOMBINANT COVID-19 VACCINE Source text for Eikon: Further company coverage:

Chinese coronavirus vaccine could be tested, manufactured in Canada

China's CanSino Biologics Inc , the company behind one of the few coronavirus vaccine candidates already in clinical trials, is collaborating with Canada's National Research Council to "pave the way" for future trials in Canada, the research council said on Tuesday.

BRIEF-Cansino Biologics Says Application For Proposed Issue Of A Shares Of Co Approved

* CANSINO BIOLOGICS INC- APPLICATION FOR PROPOSED ISSUE OF A SHARES OF CO APPROVED BY LISTING COMMITTEE FOR SCI-TECH INNOVATION BOARD Source text for Eikon: Further company coverage:

BRIEF-Cansino Biologics Says All Companies Owned By LAV Entities To Dispose Of 4.108% Of Total Issued H Shares Of Co

* INFORMED BY LAV MANAGEMENT THAT ALL CO'S OWNED BY LAV ENTITIES TO DISPOSE OF 4.108% OF TOTAL ISSUED H SHARES OF CO

BRIEF-Cansino Biologics Says Recombinant Novel Coronavirus Disease Vaccine Approved For Trial

* RECOMBINANT NOVEL CORONAVIRUS DISEASE VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR CLINICAL TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Cansino Biologics Says Co & Institute Of Biotechnology, Academy Of Military Medical Sciences Jointly Developing Recombinant Novel Coronavirus Vaccine

* CO & INSTITUTE OF BIOTECHNOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES JOINTLY DEVELOPING RECOMBINANT NOVEL CORONAVIRUS VACCINE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up